Impact of simultaneous assay, the PCNA, cyclinD1, and DNA content with specimens before and after preoperative radiotherapy on prognosis of esophageal cancer-possible incorporation into clinical TNM staging system.
OBJECTIVE
The aim of the present study is to use immunohistochemical methods to investigate the clinical implications of tumor markers in esophageal squamous cell carcinoma and evaluate their impact on prognosis.


METHODS
From November 1990 to December 1996, 47 patients were treated with preoperative radiation followed by radical esophagectomy. All patients were confirmed pathologically as suffering from squamous cell carcinoma. Immunohistochemical stain was done for PCNA, cyclinD1 protein expression and DNA content analyzed by image cytometry. Kaplan-Meier method for single prognostic factor and log-rank test was used to test the significant difference. Cox stepwise regression model and prognosis index model were used for survival analysis with multiple prognostic factors.


RESULTS
Radio-pathological change, T stage and N stage, as the traditional prognostic factors had statistical difference in 3-, 5- and 10-year survival rates. While, tumor cell proliferating marked PCNA, cyclinD1 and DNA content served as independent prognostic factors of esophageal carcinoma. There was definitely an identity between the single and multiple factor analyses. PI was more accurate to evaluate the prognosis of esophageal carcinoma.


CONCLUSIONS
It is possible that tumor cell proliferating marked PCNA, cyclinD1 and DNA content would become the endpoints for evaluating the prognosis of esophageal carcinoma.
Zhu
Shu-Chai
SC
Department of Radiation Oncology, Fourth Hospital, Hebei Medical University, Jiankanglu 12, Shijiazhuang 050011, Hebei Province, China. sczhu@heinfo.net
Li
Ren
R
Wang
Yu-Xiang
YX
Feng
Wei
W
Li
Juan
J
Qiu
Rong
R
D000328:Adult; D000368:Aged; D019938:Cyclin D1 / Q000032:analysis*; D004273:DNA, Neoplasm / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D011184:Postoperative Period; D011300:Preoperative Care; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*
D004273:DNA, Neoplasm; D018809:Proliferating Cell Nuclear Antigen; D019938:Cyclin D1